Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction
نویسندگان
چکیده
Stroke is a rare but serious complication of acute myocardial infarction (AMI). Currently, glycoprotein (GP) IIb/IIIa inhibitor is used in clinical practice for acute coronary syndromes and percutaneous coronary interventions (PCIs). The incidence of stroke in patients receiving GP IIb/IIIa inhibitor during PCIs is very low. We report the case of a 47-year-old man who presented with AMI and suffered an acute cerebral infarction after infusion of a GP IIb/IIIa inhibitor following primary PCI.
منابع مشابه
Tirofiban (glycoprotein Iib/iiia Inhibitor) in Patients with St- Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Primary percutaneous coronary intervention (PCI) is the preferred method for early restoration of blood flow in the infarct-related vessel in patients with ST-segment elevation myocardial infarction (STEMI), and adjunctive anti-platelet therapy is found to be associated with clinical outcomes following primary PCI. Glycoprotein IIb/IIIa inhibitors(GPI) act by inhibiting the final common pathway...
متن کاملThe efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
OBJECTIVES We evaluated the efficacy and safety of prasugrel and clopidogrel in the setting of a glycoprotein (GP) IIb/IIIa inhibitor. BACKGROUND Prasugrel reduced cardiovascular events as compared with clopidogrel in TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) but with increased...
متن کاملPlatelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
CONTEXT Thrombus formation on disrupted atherosclerotic plaque is the major cause of acute coronary events. Platelet inhibitors are the mainstay of drug therapy to reduce cardiac events in patients with acute coronary syndromes. The platelet glycoprotein (GP) IIb/IIIa receptor is the final common pathway of platelet aggregation. OBJECTIVES To review mechanisms of platelet activation and aggre...
متن کاملClinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor
The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in...
متن کاملPlatelet glycoprotein IIb/IIIa antagonists: pharmacology and clinical developments.
PLATELETS are critical for normal hemostasis and thrombus formation. Thrombus formation initiated by platelets plays a central role in the pathogenesis of acute coronary syndromes (unstable angina and myocardial infarction). Platelets are involved in events causing angioplasty failure and stent thrombosis and may also play an important role in restenosis through the release of potent prothrombo...
متن کامل